← brief for 2026-09-03 · Slowing decline

Impact of Dapagliflozin on Kidney Function Decline in Chronic Kidney Disease Patients: A Systematic Review.

Article A Peer reviewed Meta-analysis or large trial

Key takeaways

Researchers searched six databases and pulled together 15 randomized trials of dapagliflozin in people with chronic kidney disease. Dapagliflozin started as a diabetes drug and is now used to slow kidney damage. The review asked how much it slows the drop in kidney filtering rate (eGFR), the number that says how well the kidneys clean the blood. Pooling many randomized trials is the strongest form of evidence, though the abstract available here stops before the pooled numbers.

Who did this work

Shadravan S · Khezri R · Zarei Venovel M · Mahami-Oskouei M · Hooman N

Source

Article · PubMed, CKD progression · 2026 Jul 31
https://pubmed.ncbi.nlm.nih.gov/42679368/